Research Results Presented at NIH Conference
CHANNAHON, Ill., June 26, 2002 – In a 13-week human trial, conjugated linoleic acid (CLA) supplementation significantly increased the presence of virus specific antibodies according to research conducted by Loders Croklaan, manufacturers of Clarinol™, a leading brand of CLA. Marianne O’Shea, Ph.D., manager of nutrition and technical services at Loders Croklaan, presented the results at a National Institute of Health workshop last month. Entitled, “Perspectives on Conjugated Linoleic Acid: Current Status and Future Directions,” the conference gathered prominent CLA researchers and thought-leaders to review and discuss the biochemistry and metabolism of CLA; its biology and health effects; and the status of human trials and efficacy.
“Considerable evidence exists that CLA enhances immune function in vitro and in animal studies,” said O’Shea. “Our study clearly demonstrates stimulation of the humoral immune response by CLA supplementation as reflected by an increase in antibody level.”
Using the hepatitis B vaccination as an infection model, 75 human subjects were divided into three treatment groups who were supplemented for a 13-week period: a control group and two CLA groups who received two different ratios of the naturally occurring isomers c9,t11 and t10, c12; one group at the ratio of 50:50 and the other group at the ratio of 80:20. Those who received CLA supplementation with equal (50:50) concentrations of the active isomers performed significantly better than those in the control group or the other experimental group. In fact, at the conclusion of the study, the antibody level in those who received CLA with c9, t11 and t10, c12 in a 50:50 ratio was twice as high as those who received CLA with those isomers in an 80:20 ratio or those who received no CLA at all.
“The results of this study are very encouraging,” said O’Shea. “The influence of CLA on the immune system might be of clinical importance in the prevention and treatment of infections or allergic reactions.”
Additional research is now underway at Loders Croklaan to investigate further the findings of this initial study. Spearheaded by the NIH, which is dedicated to uncovering new knowledge that will lead to better health for everyone, the workshop was sponsored by several of its divisions including the Division of Nutrition Research Coordination; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Center for Complementary and Alternative Medicine; the National Heart, Lung and Blood Institute; the National Cancer Institute and the Office of Dietary Supplements.
Loders Croklaan is a global leader in the supply of lipid-based health ingredients (nutritionally active components of oils and fats). The company offers a variety of branded products that have resulted from their intensive lipid research program, including: Clarinol™, CLA for weight management and immune system support; Marinol™, fish oil concentrates (Omega-3, EPA, DHA) for cardiovascular health, brain development and joint health; Membranol™, fractionated lecithin (Phosphatidyl Choline) for cardiovascular health, liver health and memory improvement; Gammanol™, gamma linolenic acid (GLA) concentrates for women’s health; and Betapol™, human milk fat replacers for baby food. Headquartered in Wormerveer, The Netherlands, the company has manufacturing facilities around the world and is ISO 9001 and ISO 14001 certified. More information about Loders Croklaan and its products can be found on the Internet at www.lipidnutrition.com. Additional information about its CLA product, Clarinol™ can be found at www.clarinol.com.